Literature DB >> 16754803

Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study.

Alan S Go1, Jingrong Yang, Lynn M Ackerson, Krista Lepper, Sean Robbins, Barry M Massie, Michael G Shlipak.   

Abstract

BACKGROUND: Previous studies have associated reduced hemoglobin levels with increased adverse events in heart failure. It is unclear, however, whether this relation is explained by underlying kidney disease, treatment differences, or associated comorbidity. METHODS AND
RESULTS: We examined the associations between hemoglobin level, kidney function, and risks of death and hospitalization in persons with chronic heart failure between 1996 and 2002 within a large, integrated, healthcare delivery system in northern California. Longitudinal outpatient hemoglobin and creatinine levels and clinical and treatment characteristics were obtained from health plan records. Glomerular filtration rate (GFR; mL.min(-1).1.73 m(-2)) was estimated from the Modification of Diet in Renal Disease equation. Mortality data were obtained from state death files; heart failure admissions were identified by primary discharge diagnoses. Among 59,772 adults with heart failure, the mean age was 72 years and 46% were women. Compared with that for hemoglobin levels of 13.0 to 13.9 g/dL, the multivariable-adjusted risk of death increased with lower hemoglobin levels: an adjusted hazard ratio (HR) of 1.16 and 95% confidence interval (CI) of 1.11 to 1.21 for hemoglobin levels of 12.0 to 12.9 g/dL; HR, 1.50 and 95% CI, 1.44 to 1.57 for 11.0 to 11.9 g/dL; HR, 1.89 and 95% CI, 1.80 to 1.98 for 10.0 to 10.9; HR, 2.31 and 95% CI, 2.18 to 2.45 for 9.0 to 9.9; and HR, 3.48 and 95% CI, 3.25 to 3.73 for <9.0 g/dL. Hemoglobin levels > or = 17.0 g/dL were associated with an increased risk of death (adjusted HR, 1.42; 95% CI, 1.24 to 1.63). Compared with those with a GFR > or = 60 mL . min(-1).1.73 m(-2), persons with a GFR <45 mL.min(-1).1.73 m(-2) had an increased mortality risk: adjusted HR, 1.39 and 95% CI, 1.34 to 1.44 for 30 to 44; HR, 2.28 and 95% CI, 2.19 to 2.39 for 15 to 29; HR, 3.26 and 95% CI, 3.05 to 3.49 for <15; and HR, 2.44 and 95% CI, 2.28 to 2.61 for those on dialysis. Relations were similar for the risk of hospitalization. The findings did not differ among patients with preserved or reduced systolic function, and hemoglobin level was an independent predictor of outcomes at all levels of kidney function.
CONCLUSIONS: Very high (> or = 17 g/dL) or reduced (<13 g/dL) hemoglobin levels and chronic kidney disease independently predict substantially increased risks of death and hospitalization in heart failure, regardless of the level of systolic function. Randomized trials are needed to evaluate whether raising hemoglobin levels can improve outcomes in chronic heart failure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16754803     DOI: 10.1161/CIRCULATIONAHA.105.577577

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  169 in total

1.  Performance of claims-based algorithms for identifying heart failure and cardiomyopathy among patients diagnosed with breast cancer.

Authors:  Larry A Allen; Marianne Ulcickas Yood; Edward H Wagner; Erin J Aiello Bowles; Roy Pardee; Robert Wellman; Laurel Habel; Larissa Nekhlyudov; Robert L Davis; Adedayo A Onitilo; David J Magid
Journal:  Med Care       Date:  2014-05       Impact factor: 2.983

Review 2.  Anemia in critical illness: insights into etiology, consequences, and management.

Authors:  Shailaja J Hayden; Tyler J Albert; Timothy R Watkins; Erik R Swenson
Journal:  Am J Respir Crit Care Med       Date:  2012-01-26       Impact factor: 21.405

3.  Long-term Outcomes Associated With Implantable Cardioverter Defibrillator in Adults With Chronic Kidney Disease.

Authors:  Nisha Bansal; Adam Szpiro; Kristi Reynolds; David H Smith; David J Magid; Jerry H Gurwitz; Frederick Masoudi; Robert T Greenlee; Grace H Tabada; Sue Hee Sung; Ashveena Dighe; Alan S Go
Journal:  JAMA Intern Med       Date:  2018-03-01       Impact factor: 21.873

4.  Hospital-level variation in use of cardiovascular testing for adults with incident heart failure: findings from the cardiovascular research network heart failure study.

Authors:  Steven A Farmer; Justin Lenzo; David J Magid; Jerry H Gurwitz; David H Smith; Grace Hsu; Sue Hee Sung; Alan S Go
Journal:  JACC Cardiovasc Imaging       Date:  2014-06-18

5.  Anemia of aging: the role of chronic inflammation and cancer.

Authors:  Luigi Ferrucci; Lodovico Balducci
Journal:  Semin Hematol       Date:  2008-10       Impact factor: 3.851

6.  The prognostic value of anemia in patients with diastolic heart failure.

Authors:  Faramarz Tehrani; Anita Phan; Ryan Morrissey; Christopher Chien; Asim Rafique; Ernst R Schwarz
Journal:  Tex Heart Inst J       Date:  2009

7.  Association between deteriorated renal function and long-term clinical outcomes after percutaneous coronary intervention.

Authors:  Manabu Ogita; Kenichi Sakakura; Tomohiro Nakamura; Hiroshi Funayama; Hiroshi Wada; Ryo Naito; Yoshitaka Sugawara; Norifumi Kubo; Junya Ako; Shin-ichi Momomura
Journal:  Heart Vessels       Date:  2011-08-06       Impact factor: 2.037

8.  Comorbid Heart Failure and Renal Impairment: Epidemiology and Management.

Authors:  Pupalan Iyngkaran; Merlin Thomas; William Majoni; Nagesh S Anavekar; Claudio Ronco
Journal:  Cardiorenal Med       Date:  2012-10-31       Impact factor: 2.041

9.  Guideline concordance of testing for hyperkalemia and kidney dysfunction during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure.

Authors:  Larry A Allen; Susan M Shetterly; Pamela N Peterson; Jerry H Gurwitz; David H Smith; David W Brand; Diane L Fairclough; John S Rumsfeld; Frederick A Masoudi; David J Magid
Journal:  Circ Heart Fail       Date:  2013-11-26       Impact factor: 8.790

10.  Contemporary prevalence and correlates of incident heart failure with preserved ejection fraction.

Authors:  Jerry H Gurwitz; David J Magid; David H Smith; Robert J Goldberg; David D McManus; Larry A Allen; Jane S Saczynski; Micah L Thorp; Grace Hsu; Sue Hee Sung; Alan S Go
Journal:  Am J Med       Date:  2013-03-14       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.